SLC47A1

Summary

SLC47A1 (solute carrier family 47 member 1, HGNC:25588) is a protein-coding gene on chromosome 17p11.2, encoding Multidrug and toxin extrusion protein 1 (Q96FL8). Multidrug efflux pump that functions as a H(+)/organic cation antiporter.

This gene is located within the Smith-Magenis syndrome region on chromosome 17. It encodes a protein of unknown function.

Source: NCBI Gene 55244 — RefSeq curated summary.

At a glance

• GWAS associations: 20
• Clinical variants (ClinVar): 96 total
• Druggable target: yes — 47 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_018242

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25588
Approved symbol	SLC47A1
Name	solute carrier family 47 member 1
Location	17p11.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ10847, MATE1
Ensembl gene	ENSG00000142494
Ensembl biotype	protein_coding
OMIM	609832
Entrez	55244

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 8 protein_coding, 5 retained_intron, 3 protein_coding_CDS_not_defined

ENST00000270570, ENST00000395585, ENST00000436810, ENST00000495425, ENST00000497548, ENST00000571335, ENST00000573009, ENST00000574596, ENST00000575023, ENST00000575362, ENST00000575377, ENST00000576095, ENST00000581558, ENST00000584348, ENST00000901046, ENST00000943824

RefSeq mRNA: 1 — MANE Select: NM_018242 NM_018242

CCDS: CCDS11209

Canonical transcript exons

ENST00000270570 — 17 exons

Exon	Start	End
ENSE00001836672	19577327	19579034
ENSE00002277438	19533854	19534074
ENSE00003459042	19555593	19555690
ENSE00003481665	19555995	19556062
ENSE00003505639	19555212	19555309
ENSE00003512581	19566790	19566859
ENSE00003545175	19572780	19572861
ENSE00003561496	19551424	19551468
ENSE00003569548	19567096	19567228
ENSE00003605240	19560418	19560493
ENSE00003620413	19546435	19546503
ENSE00003621711	19542393	19542494
ENSE00003625114	19555796	19555909
ENSE00003627735	19549635	19549677
ENSE00003641639	19547985	19548133
ENSE00003655212	19560188	19560296
ENSE00003683381	19571478	19571572

Expression profiles

Bgee: expression breadth ubiquitous, 230 present calls, max score 98.25.

FANTOM5 (CAGE): breadth broad, TPM avg 3.5221 / max 203.7094, expressed in 862 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
159848	3.2326	822
159849	0.2407	115
159847	0.0489	12

Top tissues by expression

276 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right adrenal gland cortex	UBERON:0035827	98.25	gold quality
nephron tubule	UBERON:0001231	97.73	gold quality
right adrenal gland	UBERON:0001233	97.71	gold quality
adrenal cortex	UBERON:0001235	97.67	gold quality
left adrenal gland cortex	UBERON:0035825	97.50	gold quality
left adrenal gland	UBERON:0001234	97.44	gold quality
kidney epithelium	UBERON:0004819	96.97	gold quality
adrenal gland	UBERON:0002369	96.42	gold quality
renal glomerulus	UBERON:0000074	96.23	gold quality
metanephric glomerulus	UBERON:0004736	95.93	gold quality
right lobe of liver	UBERON:0001114	95.63	gold quality
liver	UBERON:0002107	95.06	gold quality
adult organism	UBERON:0007023	94.31	gold quality
adult mammalian kidney	UBERON:0000082	93.41	gold quality
adrenal tissue	UBERON:0018303	92.89	gold quality
endocervix	UBERON:0000458	91.58	gold quality
kidney	UBERON:0002113	91.49	gold quality
gastrocnemius	UBERON:0001388	90.32	gold quality
muscle of leg	UBERON:0001383	89.98	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	89.55	gold quality
cortex of kidney	UBERON:0001225	89.35	gold quality
upper leg skin	UBERON:0004262	88.99	gold quality
muscle organ	UBERON:0001630	88.82	gold quality
skeletal muscle organ	UBERON:0014892	88.82	gold quality
hindlimb stylopod muscle	UBERON:0004252	88.20	gold quality
metanephros	UBERON:0000081	88.09	gold quality
vastus lateralis	UBERON:0001379	87.55	gold quality
biceps brachii	UBERON:0001507	87.33	gold quality
adenohypophysis	UBERON:0002196	86.63	gold quality
quadriceps femoris	UBERON:0001377	86.21	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-119	yes	47.51
E-ANND-3	yes	5.59

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AP1, KLF12, NKX2-5, USF1

miRNA regulators (miRDB)

50 targeting SLC47A1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-552-5P	99.93	68.56	1583
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-323A-3P	99.79	70.30	1739
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-12129	99.72	67.45	1311
HSA-MIR-33A-3P	99.70	70.27	3362
HSA-MIR-30B-3P	99.70	65.76	2325
HSA-MIR-3689A-3P	99.70	65.73	2306
HSA-MIR-3689B-3P	99.70	65.71	2311
HSA-MIR-3689C	99.70	65.71	2311
HSA-MIR-6779-5P	99.70	65.76	2363
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-10393-5P	99.65	68.01	1368
HSA-MIR-6512-3P	99.65	66.07	1468
HSA-MIR-6720-5P	99.65	66.22	1459
HSA-MIR-4666B	99.64	68.69	1282
HSA-MIR-4261	99.59	70.30	3415
HSA-MIR-3942-3P	99.57	69.03	2854
HSA-MIR-6733-3P	99.54	67.80	1281
HSA-MIR-7106-5P	99.53	67.47	3574
HSA-MIR-4452	99.50	68.45	1493
HSA-MIR-183-3P	99.41	69.41	1598
HSA-MIR-5690	99.25	67.58	1012
HSA-MIR-6797-3P	99.17	66.94	668

Literature-anchored findings (GeneRIF, showing 40)

• MATE1 appears to be the long searched for polyspecific organic cation exporter that directly transports toxic organic cations into urine and bile. (PMID:16330770)
• an oppositely directed H(+) gradient serves as a driving force of tetraethylammonium transport via rMATE1 (PMID:17047166)
• The results suggest that hOCT2 and hMATE1 mediate paraquat transport in the kidney. (PMID:17495125)
• hMATE1 and hMATE2-K function together as a detoxication system, by mediating the tubular secretion of intracellular ionic compounds across the brush-border membranes of the kidney. (PMID:17509534)
• Sp1 functions as basal transcriptional regulator of human and rat MATE1 gene through two GC boxes. May be conserved among species. We have identified rSNP of hMATE1 gene (G-32A) (belonging to Sp1-binding site) that affects promoter activity. (PMID:17855482)
• The molecular basis of substrate recognition by MATE1 was investigated via amino acid substitution in the conserved transmembrane regions. (PMID:18305230)
• These findings suggested that the loss of transport activities of the MATE1 G64D and MATE2-K G211V variants were due to the alteration of protein expression in cell surface membranes. (PMID:19158817)
• Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. (PMID:19172157)
• Guanin/adenine single nucleotide polymorphism is associated with a reduction in A1C level suggesting it role in the pharmacokinetics of metformin in diabetics. (PMID:19228809)
• the rate of transcription of MATE1 is regulated by AP-1 and AP-2rep and that a common promoter variant, g.-66T>C may affect the expression level of MATE1 in human kidney, and ultimately result in variation in drug disposition and response. (PMID:19745787)
• interaction between polymorphisms and OCT1 polymorphisms on the glucose lowering effect of metformin (PMID:19898263)
• The purpose of this study was to evaluate the effects of heterozygous MATE variants on the disposition of metformin in mice and humans. (PMID:20016398)
• 4’,6-diamidino-2-phenylindole (DAPI) can be used as a probe substrate for rapid assays of the functionality of the human MATE1 (PMID:20047987)
• This study showed that coordinate function of MATE1 with OCT2 likely contributes to the vectorial renal elimination of organic cationic drugs and that altered activity of MATE1 should be considered as a determinant of renal cationic drug elimination. (PMID:20053795)
• characterization of MATE1: kinetic analysis of transport of cimetidine and tetraethylammonium; inhibitors; comparison to hMATE2-K and rMATE1 (PMID:20067714)
• The results suggest that agmatine disposition may be influenced by hOCT2 and hMATE1, two transporters critical in the renal elimination of xenobiotic compounds. (PMID:21128598)
• Homozygous MATE1 variant could be one of the risk factors for metformin-induced lactic acidosis. (PMID:22242910)
• The 808G>T single-nucleotide polymorphism in OCT2 ameliorated cisplatin-induced nephrotoxicity without alteration of disposition, whereas the rs2289669 G>A single-nucleotide polymorphism in MATE1 had no effect on cisplatin toxicity. (PMID:22569819)
• Twelve transmembrane helices form the functional core of mammalian MATE1 (multidrug and toxin extruder 1) protein. (PMID:22722930)
• Seven polymorphisms in OCT1, OCT2, and MATE1 genes were compared between 53 type 2 diabetes patients with side effects of metformin and 193 metformin users without symptoms of metformin intolerance. (PMID:22735389)
• Twenty percent of patients with diabetes that are homozygous for A-allele of SLC47A1 had twofold reduction in HbA1c in comparison with the patients carrying G-allele. (PMID:22882994)
• The effect of novel promoter variants in MATE1 … on the pharmacokinetics and pharmacodynamics of metformin (PMID:23267855)
• Decreasing expression of OCT3 and MATE1 in human placenta indicates these transporters may play a role in fetal protection preferentially at earlier stages of gestation. (PMID:23303678)
• The results confirmed that OAT1, OAT3, OCT2, MATE1, and MATE2-K were coexpressed in tubular epithelial cells. (PMID:23630107)
• ADMA and L-arginine are substrates of human CAT2A, CAT2B, OCT2 and MATE1. Transport kinetics of CAT2A, CAT2B, and OCT2 indicate a low affinity, high capacity transport, which may be relevant for renal and hepatic elimination of ADMA or L-arginine (PMID:23864433)
• MATE1 is a membrane transporter for quercetin.MATE1 was highly expressed in peroxisomes and the endoplasmic reticulum as well as in plasma membranes in the liver and intestine. (PMID:25241911)
• Disease progression according to RECIST was also more frequent in carriers of at least one polymorphic MATE1 A-allele (44%) as compared with homozygous carriers of the wild-type G-allele (12.5%) (P=0.07). OCT1 and MATE1 were not associated with PFS. (PMID:25753371)
• MRNA levels of multidrug and toxin extrusion protein 1 (MATE1 or SLC47A1, encoded by 1 of the 11 genes) were significantly lower in patients with FILI. (PMID:25862351)
• SLC47A1 rs2289669 G>A variants improve the glucose-lowering effect of metformin through slowing its excretion in type 2 diabetes populations. (PMID:26004431)
• MATE1 sequesters organic cations within an intracellular compartment that has no influence on secretion in renal proximal tubules. (PMID:26538438)
• MATE1 rs2289669 may be a significant determinant in the renal clearance of metformin in the case of transporter-mediated drug interactions (PMID:26784938)
• MATE1 mRNA levels in peripheral blood cells were significantly higher in patients carrying the minor allele of rs2453579, but not rs2252281, compared to those with other genotypes (PMID:27025966)
• Pazopanib inhibits OCT2, MATE1 and MATE2-K, which are involved in cisplatin secretion into urine, potentiating cisplatin toxicity. (PMID:27178732)
• This study did not identify any of these known SLC47A1 coding SNPs in the Xhosa individuals who participated in this study. (PMID:27226103)
• The impact of assay conditions on IC50 determination is negligible, kinetic characteristics differ among used test substrates, and substrate-dependent inhibition exists for MATE1 and MATE2-K, giving valuable insight into the assessment of clinically relevant MATE-mediated drug interactions in vitro. (PMID:27271370)
• substrate identity exerts comparatively little influence on ligand interaction with MATE1. (PMID:27418674)
• MATE1 polymorphisms were associated with hematological toxicity in non-small cell lung cancer patients. (PMID:27590272)
• MATE1 is the major transporter for the cellular uptake of imatinib and crucial for the therapeutic success in CML patients. We suggest that the detailed analysis of MATE1 expression levels and mutations could be a predictor for the response to imatinib therapy. (PMID:27635733)
• genetic association studies in population in China: Data confirm that an SNP in an intron of SLC47A1 (rs2289669) is associated with hypoglycemic response to metformin in patients with newly diagnosed type 2 diabetes; differential increases in basal GLP1 plasma levels are also related to this SNP. (SLC47A1 = solute carrier family 47 member 1; GLP1 = glucagon-like peptide-1) (PMID:28321905)
• The combination of ENT1, MATE1 and OCT2 SNPs may serve as a predictive and prognostic marker in metastatic colorectal carcinoma patients treated with TAS-102. (PMID:28992563)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	slc47a1	ENSDARG00000046012
danio_rerio	slc47a4	ENSDARG00000079340
mus_musculus	Slc47a1	ENSMUSG00000010122
rattus_norvegicus	Slc47a1	ENSRNOG00000057404

Paralogs (1): SLC47A2 (ENSG00000180638)

Protein

Protein identifiers

Multidrug and toxin extrusion protein 1 — Q96FL8 (reviewed: Q96FL8)

Alternative names: Solute carrier family 47 member 1

All UniProt accessions (5): Q96FL8, E7EX57, I3L345, J3KRZ3, J3KSS8

UniProt curated annotations — full annotation on UniProt →

Function. Multidrug efflux pump that functions as a H(+)/organic cation antiporter. Plays a physiological role in the excretion of cationic compounds including endogenous metabolites, drugs, toxins through the kidney and liver, into urine and bile respectively. Mediates the efflux of endogenous compounds such as creatinine, vitamin B1/thiamine, agmatine and estrone-3-sulfate. May also contribute to regulate the transport of cationic compounds in testis across the blood-testis-barrier.

Subcellular location. Cell membrane. Apical cell membrane.

Tissue specificity. Widely expressed. The highest expression is found in adrenal gland, and to a lower extent in liver, skeletal muscle and kidney. In testis, primarily localized throughout the adluminal compartment of the seminiferous tubules with expression at the peritubular myoid cells and Leydig cells.

Miscellaneous. Mediates the efflux of cationic compounds such as the model cations, tetraethylammonium (TEA), the neurotoxin 1-methyl-4-phenylpyridinium (MPP), the platinum-based drugs cisplatin and oxaliplatin, the drugs procainamide, acyclovir and topotecan, or weak bases that are positively charged at physiological pH, such as cimetidine or the antidiabetic drug metformin.

Similarity. Belongs to the multi antimicrobial extrusion (MATE) (TC 2.A.66.1) family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q96FL8-1	1	yes
Q96FL8-2	2
Q96FL8-3	3

RefSeq proteins (1): NP_060712* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002528	MATE_fam	Family
IPR045069	MATE_euk	Family

Pfam: PF01554

Catalyzed reactions (Rhea), 4 shown:

• thiamine(out) + H(+)(in) = thiamine(in) + H(+)(out) (RHEA:71271)
• agmatine(in) + H(+)(out) = agmatine(out) + H(+)(in) (RHEA:72127)
• estrone 3-sulfate(in) + H(+)(out) = estrone 3-sulfate(out) + H(+)(in) (RHEA:72139)
• creatinine(in) + H(+)(out) = creatinine(out) + H(+)(in) (RHEA:72183)

UniProt features (52 total): topological domain 14, transmembrane region 13, mutagenesis site 8, sequence variant 6, sequence conflict 4, splice variant 3, chain 1, region of interest 1, compositionally biased region 1, modified residue 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
9R1F	ELECTRON MICROSCOPY	2.31
9R1G	ELECTRON MICROSCOPY	2.95
9R1E	ELECTRON MICROSCOPY	3.2
9R10	ELECTRON MICROSCOPY	3.3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96FL8-F1	85.87	0.77

Antibody-complex structures (SAbDab): 4 — 9R10, 9R1E, 9R1F, 9R1G

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 1

Mutagenesis-validated functional residues (8):

Position	Phenotype
273	abolishes membrane subcellular location. abolishes tea transport.
273	does not affect membrane subcellular location. decreases tea transport. higher affinity for cimetidine and reduced affin
273	no change in subcellular location and abolition of mate1-dependent tea transport activity.
278	does not affect membrane subcellular location. abolishes tea transport.
278	does not affect membrane subcellular location. decreases tea transport.
299	decreased tea and metformin uptake.
300	does not affect membrane subcellular location. decreases tea transport.
389	does not affect membrane subcellular location. decreases tea transport.

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-549127	SLC-mediated transport of organic cations
R-HSA-425366
R-HSA-382551	Transport of small molecules
R-HSA-425407	SLC-mediated transmembrane transport

MSigDB gene sets: 161 (showing top): GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_UP, CLAUS_PGR_POSITIVE_MENINGIOMA_UP, GOBP_XENOBIOTIC_TRANSMEMBRANE_TRANSPORT, GOBP_AMINO_ACID_TRANSMEMBRANE_TRANSPORT, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_ORGANIC_ACID_TRANSPORT, MODULE_205, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM4, GOBP_AMINO_ACID_TRANSPORT, GOBP_BASIC_AMINO_ACID_TRANSPORT, GOBP_DETOXIFICATION, GOBP_ORGANIC_ANION_TRANSPORT, GOBP_SULFUR_COMPOUND_TRANSPORT, GOMF_PROTON_TRANSMEMBRANE_TRANSPORTER_ACTIVITY, GOBP_VITAMIN_TRANSPORT

GO Biological Process (13): xenobiotic transmembrane transport (GO:0006855), obsolete organic cation transport (GO:0015695), putrescine transport (GO:0015847), xenobiotic transport (GO:0042908), transmembrane transport (GO:0055085), amino acid import across plasma membrane (GO:0089718), L-arginine import across plasma membrane (GO:0097638), L-alpha-amino acid transmembrane transport (GO:1902475), xenobiotic detoxification by transmembrane export across the plasma membrane (GO:1990961), thiamine transmembrane transport (GO:0071934), monoatomic cation transmembrane transport (GO:0098655), proton transmembrane transport (GO:1902600), L-arginine transmembrane transport (GO:1903826)

GO Molecular Function (10): obsolete organic cation transmembrane transporter activity (GO:0015101), L-amino acid transmembrane transporter activity (GO:0015179), thiamine transmembrane transporter activity (GO:0015234), antiporter activity (GO:0015297), putrescine transmembrane transporter activity (GO:0015489), transmembrane transporter activity (GO:0022857), xenobiotic transmembrane transporter activity (GO:0042910), L-arginine transmembrane transporter activity (GO:0061459), polyspecific organic cation:proton antiporter activity (GO:0140968), protein binding (GO:0005515)

GO Cellular Component (4): plasma membrane (GO:0005886), membrane (GO:0016020), basolateral plasma membrane (GO:0016323), apical plasma membrane (GO:0016324)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
SLC-mediated transmembrane transport	1
Transport of small molecules	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
xenobiotic transport	2
transmembrane transport	2
transport	2
amino acid transmembrane transport	2
L-arginine transmembrane transport	2
L-alpha-amino acid transmembrane transport	2
plasma membrane region	2
polyamine transport	1
cellular process	1
import across plasma membrane	1
amino acid import across plasma membrane	1
L-amino acid transport	1
carboxylic acid transmembrane transport	1
xenobiotic export from cell	1
detoxification	1
export across plasma membrane	1
thiamine transport	1
vitamin transmembrane transport	1
azole transmembrane transport	1
pyrimidine-containing compound transmembrane transport	1
monoatomic cation transport	1
monoatomic ion transmembrane transport	1
monoatomic cation transmembrane transport	1
basic amino acid transmembrane transport	1
amino acid transmembrane transporter activity	1
carboxylic acid transmembrane transporter activity	1
thiamine transmembrane transport	1
vitamin transmembrane transporter activity	1
azole transmembrane transporter activity	1
sulfur compound transmembrane transporter activity	1
secondary active transmembrane transporter activity	1
polyamine transmembrane transporter activity	1
putrescine transport	1
transporter activity	1
transmembrane transporter activity	1
basic amino acid transmembrane transporter activity	1
L-amino acid transmembrane transporter activity	1
proton transmembrane transporter activity	1
antiporter activity	1
binding	1

Protein interactions and networks

STRING

1598 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC47A1	SLC22A2	O15244	888
SLC47A1	SLC22A1	O15245	856
SLC47A1	SLC22A8	Q8TCC7	802
SLC47A1	SLCO1B3	Q9NPD5	763
SLC47A1	SLCO1B1	Q9Y6L6	760
SLC47A1	SLC22A9	Q8IVM8	760
SLC47A1	SLC22A11	Q9NSA0	750
SLC47A1	SLCO2B1	O94956	741
SLC47A1	SLC22A4	Q9H015	734
SLC47A1	SLC22A6	Q4U2R8	733
SLC47A1	SLC29A4	Q7RTT9	729
SLC47A1	SLC22A7	Q9Y694	729
SLC47A1	SLC22A3	O75751	716
SLC47A1	ABCG2	Q9UNQ0	715
SLC47A1	SLCO4C1	Q6ZQN7	703

IntAct

39 interactions, top by confidence:

A	B	Type	Score
SLC47A1	FXYD6	psi-mi:“MI:0915”(physical association)	0.560
GPR21	TMEM120B	psi-mi:“MI:0914”(association)	0.530
SLC39A4	TMEM120B	psi-mi:“MI:0914”(association)	0.530
LYPD6	PLXNB2	psi-mi:“MI:0914”(association)	0.530
TMPRSS12	FZD6	psi-mi:“MI:0914”(association)	0.530
CHRND	TPST2	psi-mi:“MI:0914”(association)	0.530
GABRA3	HLA-C	psi-mi:“MI:0914”(association)	0.530
SLC47A1	DES	psi-mi:“MI:0915”(physical association)	0.400
TTYH1	TMEM223	psi-mi:“MI:0914”(association)	0.350
TSPAN15	TMEM223	psi-mi:“MI:0914”(association)	0.350
TNFSF18	TMEM120B	psi-mi:“MI:0914”(association)	0.350
LRRC55	TMEM120B	psi-mi:“MI:0914”(association)	0.350
TNFRSF10C	SLC22A23	psi-mi:“MI:0914”(association)	0.350
ZACN	FAM234B	psi-mi:“MI:0914”(association)	0.350
SLC47A1	FAM234B	psi-mi:“MI:0914”(association)	0.350
TCTN2	TMEM131L	psi-mi:“MI:0914”(association)	0.350
LLCFC1	POTEF	psi-mi:“MI:0914”(association)	0.350
KLRC4	RAP1BL	psi-mi:“MI:0914”(association)	0.350
KLRC1	METTL15	psi-mi:“MI:0914”(association)	0.350
PTH2R	METTL15	psi-mi:“MI:0914”(association)	0.350
SLC39A12		psi-mi:“MI:0914”(association)	0.350
NKAIN1	GPR89A	psi-mi:“MI:0914”(association)	0.350
KIR2DL4	GPR89A	psi-mi:“MI:0914”(association)	0.350
HTR3C	GET1	psi-mi:“MI:0914”(association)	0.350
SLC17A2	ABCD4	psi-mi:“MI:0914”(association)	0.350
KLRC2	CLGN	psi-mi:“MI:0914”(association)	0.350
CD3D	CLGN	psi-mi:“MI:0914”(association)	0.350
KLRC3	RNF13	psi-mi:“MI:0914”(association)	0.350
HTR3A	EXTL3	psi-mi:“MI:0914”(association)	0.350
SLC22A2	FADS1	psi-mi:“MI:0914”(association)	0.350

BioGRID (116): SLC47A1 (Affinity Capture-MS), SLC47A1 (Affinity Capture-MS), SLC47A1 (Affinity Capture-MS), SLC47A1 (Affinity Capture-MS), SLC47A1 (Affinity Capture-MS), SLC47A1 (Affinity Capture-MS), SLC47A1 (Affinity Capture-MS), SLC47A1 (Affinity Capture-MS), SLC47A1 (Affinity Capture-MS), SLC47A1 (Affinity Capture-MS), SLC47A1 (Affinity Capture-MS), SLC47A1 (Affinity Capture-MS), SLC47A1 (Affinity Capture-MS), SLC47A1 (Affinity Capture-MS), SLC47A1 (Affinity Capture-MS)

ESM2 similar proteins: A1L1P9, A4IIS8, A7KAU2, A7KAU3, A8I499, B3TP03, B5D5N9, F4J158, F4JH46, F4KBM7, H9BZ66, O49660, O64759, P18581, P30823, P30825, P31637, P38142, P38767, P52569, P53793, P53794, Q05360, Q09143, Q10917, Q16928, Q17320, Q22397, Q27256, Q2UVJ5, Q3EAQ5, Q3V050, Q5I0E9, Q5PR34, Q5R7E4, Q5RFD2, Q66KG0, Q84MA5, Q86VL8, Q8K0H1

Diamond homologs: A1L1P9, A4IIS8, A7KAU2, A7KAU3, F4IHU9, O80695, Q10085, Q3V050, Q4PSF4, Q5I0E9, Q5R7E4, Q5RFD2, Q86VL8, Q8K0H1, Q8L731, Q94AL1, Q96FL8, Q9C9M8, Q9FH21, Q9FHB6, Q9LE20, Q9LUH2, Q9LUH3, Q9LVD9, Q9LYT3, Q9SZE2, Q9USK3, Q9UT92, Q9ZVH5, F4HQ05, O49660, O82752, Q9C994, Q9FJ87, Q9SIA5, F4HZH9, F4JH46, F4JKB9, Q05497, Q1PFG9

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 59 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of natural killer cell mediated cytotoxicity	5	51.1×	1e-05
monoatomic ion transmembrane transport	5	18.9×	6e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

96 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	71
Likely benign	7
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

2921 predictions. Top by Δscore:

Variant	Effect	Δscore
17:19534072:GCG:G	donor_gain	1.0000
17:19534075:G:GG	donor_gain	1.0000
17:19534079:G:GG	donor_gain	1.0000
17:19542391:A:AG	acceptor_gain	1.0000
17:19542392:G:GA	acceptor_gain	1.0000
17:19542392:GTT:G	acceptor_gain	1.0000
17:19542392:GTTC:G	acceptor_gain	1.0000
17:19542492:GCG:G	donor_gain	1.0000
17:19542494:GGTA:G	donor_loss	1.0000
17:19542495:G:GA	donor_loss	1.0000
17:19542495:G:GG	donor_gain	1.0000
17:19542496:T:TC	donor_loss	1.0000
17:19547973:T:TA	acceptor_gain	1.0000
17:19547975:T:TA	acceptor_gain	1.0000
17:19547978:A:AG	acceptor_gain	1.0000
17:19547979:C:G	acceptor_gain	1.0000
17:19547983:A:AG	acceptor_gain	1.0000
17:19547984:G:GG	acceptor_gain	1.0000
17:19547984:GAC:G	acceptor_gain	1.0000
17:19548130:CCAGG:C	donor_loss	1.0000
17:19548134:G:T	donor_loss	1.0000
17:19548135:T:G	donor_loss	1.0000
17:19534073:CGG:C	donor_loss	0.9900
17:19534074:GGT:G	donor_loss	0.9900
17:19534075:G:GA	donor_loss	0.9900
17:19534078:AGT:A	donor_loss	0.9900
17:19542388:CCCA:C	acceptor_loss	0.9900
17:19542389:CCA:C	acceptor_loss	0.9900
17:19542390:CA:C	acceptor_loss	0.9900
17:19542392:GT:G	acceptor_gain	0.9900

AlphaMissense

3662 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:19542432:A:C	S59R	0.994
17:19542434:C:A	S59R	0.994
17:19542434:C:G	S59R	0.994
17:19555852:A:C	S266R	0.990
17:19555854:C:A	S266R	0.990
17:19555854:C:G	S266R	0.990
17:19555879:T:A	W275R	0.989
17:19555879:T:C	W275R	0.989
17:19542486:G:C	A77P	0.988
17:19542487:C:A	A77E	0.985
17:19546469:G:A	G91D	0.985
17:19560480:T:C	F365L	0.985
17:19560482:T:A	F365L	0.985
17:19560482:T:G	F365L	0.985
17:19555906:A:C	S284R	0.983
17:19555908:T:A	S284R	0.983
17:19555908:T:G	S284R	0.983
17:19571483:T:A	W439R	0.983
17:19571483:T:C	W439R	0.983
17:19571554:G:C	W462C	0.983
17:19571554:G:T	W462C	0.983
17:19542474:G:C	A73P	0.982
17:19546468:G:C	G91R	0.982
17:19560233:G:C	A323P	0.981
17:19546462:G:A	G89R	0.980
17:19546462:G:C	G89R	0.980
17:19567120:G:T	G401W	0.979
17:19542448:G:A	G64D	0.978
17:19546450:G:C	G85R	0.977
17:19542484:T:C	L76P	0.976

dbSNP variants (sampled 300 via entrez): RS1000015147 (17:19547264 G>A), RS1000017537 (17:19546063 T>C), RS1000100362 (17:19535018 G>C), RS1000156855 (17:19554417 C>T), RS1000211065 (17:19559227 A>T), RS1000228758 (17:19578325 C>T), RS1000272096 (17:19569043 C>T), RS1000282941 (17:19541323 T>C,G), RS1000290188 (17:19571779 G>A), RS1000317767 (17:19559789 T>C), RS1000329613 (17:19576019 G>T), RS1000370241 (17:19534983 G>A,C), RS1000402339 (17:19541855 A>C), RS1000475375 (17:19565409 C>T), RS1000492018 (17:19570848 G>C)

Disease associations

OMIM: gene MIM:609832 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

20 associations (top):

Study	Trait	p-value
GCST003372_57	Glomerular filtration rate (creatinine)	3.000000e-11
GCST003401_24	Glomerular filtration rate in non diabetics (creatinine)	3.000000e-13
GCST004292_34	Glomerular filtration rate (creatinine)	5.000000e-12
GCST004627_170	Lymphocyte count	6.000000e-09
GCST007344_5	Estimated glomerular filtration rate	5.000000e-11
GCST007354_19	Intracranial aneurysm	1.000000e-08
GCST007876_139	Estimated glomerular filtration rate	3.000000e-21
GCST007877_18	Creatinine levels	1.000000e-08
GCST008058_161	Estimated glomerular filtration rate	1.000000e-45
GCST008059_124	Estimated glomerular filtration rate	5.000000e-40
GCST008064_7	Chronic kidney disease	3.000000e-07
GCST008745_18	Estimated glomerular filtration rate in non-diabetics	5.000000e-14
GCST008747_154	Estimated glomerular filtration rate	5.000000e-25
GCST008747_85	Estimated glomerular filtration rate	3.000000e-28
GCST008971_58	Urate levels	7.000000e-10
GCST008972_31	Urate levels	3.000000e-10
GCST90002388_491	Lymphocyte count	1.000000e-15
GCST90002389_224	Lymphocyte percentage of white cells	4.000000e-12
GCST90002399_284	Neutrophil percentage of white cells	6.000000e-11
GCST90002404_350	Red cell distribution width	7.000000e-12

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004587	lymphocyte count
EFO:0004531	urate measurement
EFO:0007993	lymphocyte percentage of leukocytes
EFO:0007990	neutrophil percentage of leukocytes
EFO:0009188	Red cell distribution width

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL1743126 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

47 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 578,889 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1017	TELMISARTAN	4	27,457
CHEMBL11	IMIPRAMINE	4	48,893
CHEMBL1106	EPINASTINE	4	8,530
CHEMBL1200629	VECURONIUM BROMIDE	4	5,399
CHEMBL128	SUMATRIPTAN	4	28,367
CHEMBL1294	QUINIDINE	4	71,943
CHEMBL134	CLONIDINE	4	97,993
CHEMBL1393	SPIRONOLACTONE	4	49,171
CHEMBL1502	PANTOPRAZOLE	4	14,689
CHEMBL163	RITONAVIR	4	53,773
CHEMBL1732	DIHYDROERGOTAMINE	4	12,897
CHEMBL1790041	RANITIDINE	4	30,599
CHEMBL2	PRAZOSIN	4	31,107
CHEMBL219916	DOMPERIDONE	4	18,305
CHEMBL256907	MARAVIROC	4	5
CHEMBL289469	GRANISETRON	4	431
CHEMBL290106	BITHIONOL	4	6,439
CHEMBL296419	ASTEMIZOLE	4	21,577
CHEMBL30	CIMETIDINE	4	47,191
CHEMBL339427	TUBOCURARINE	4	4,123
CHEMBL364713	NOSCAPINE	4
CHEMBL46	ONDANSETRON	4
CHEMBL481	IRINOTECAN	4
CHEMBL49	BUSPIRONE	4
CHEMBL517	DISOPYRAMIDE	4
CHEMBL5315124	LEVOFLOXACIN	4
CHEMBL55	PENTAMIDINE	4
CHEMBL58	MITOXANTRONE	4
CHEMBL603	ZAFIRLUKAST	4
CHEMBL660	AMANTADINE	4

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

2 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs2252281	Efficacy	3	metformin	Diabetes Mellitus;Type 2;Polycystic Ovary Syndrome
rs2289669	Efficacy	3	metformin	Diabetes Mellitus;Type 2;Polycystic Ovary Syndrome

PharmGKB variants

3 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs2252281	SLC47A1	3	3.50	1	metformin
rs2289669	SLC47A1, SNORA59B	3	4.00	1	metformin
rs8065082	SLC47A1		0.00	0

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — SLC47 family of multidrug and toxin extrusion transporters

Most potent curated ligand interactions (2 total), top 2:

Ligand	Action	Affinity	Parameter
pyrimethamine	Inhibition	7.1	pKi
cimetidine	Inhibition	6.0	pKi

ChEMBL bioactivities

54 potent at pChembl≥5 of 70 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.52	IC50	30	nM	ONDANSETRON
7.40	IC50	40	nM	IMATINIB
7.30	IC50	50	nM	IMATINIB
7.10	IC50	80	nM	RITONAVIR
6.82	IC50	150	nM	ONDANSETRON
6.80	IC50	160	nM	ONDANSETRON
6.72	IC50	190	nM	MITOXANTRONE
6.46	IC50	350	nM	IMATINIB
6.40	IC50	400	nM	MITOXANTRONE
6.39	IC50	410	nM	PENTAMIDINE
6.30	IC50	500	nM	GABEXATE
6.28	IC50	530	nM	MITOXANTRONE
6.19	IC50	650	nM	NIFEKALANT
6.16	IC50	700	nM	CHLORHEXIDINE
6.12	IC50	760	nM	FAMOTIDINE
5.96	IC50	1100	nM	TACRINE
5.96	IC50	1100	nM	NIFEKALANT
5.96	IC50	1100	nM	EPINASTINE
5.92	IC50	1200	nM	CIMETIDINE
5.89	IC50	1300	nM	TOPOTECAN
5.89	IC50	1300	nM	ZAFIRLUKAST
5.80	IC50	1600	nM	RISPERIDONE
5.80	IC50	1600	nM	PRAZOSIN
5.77	IC50	1700	nM	INDINAVIR
5.77	IC50	1700	nM	BUSPIRONE
5.72	IC50	1900	nM	INDINAVIR
5.72	IC50	1900	nM	VECURONIUM BROMIDE
5.70	IC50	2000	nM	PENTAMIDINE
5.70	IC50	2000	nM	CHEMBL5194558
5.68	IC50	2100	nM	RITONAVIR
5.68	IC50	2100	nM	IRINOTECAN
5.66	IC50	2200	nM	CIMETIDINE
5.64	IC50	2300	nM	DOMPERIDONE
5.57	IC50	2700	nM	PENTAMIDINE
5.57	IC50	2700	nM	CHEMBL5563848
5.55	IC50	2800	nM	PANTOPRAZOLE
5.55	IC50	2800	nM	DIHYDROERGOTAMINE
5.54	IC50	2900	nM	CAMOSTAT
5.37	IC50	4300	nM	IRINOTECAN
5.36	IC50	4400	nM	RITONAVIR
5.30	IC50	5000	nM	GRANISETRON
5.28	IC50	5200	nM	BITHIONOL
5.24	IC50	5700	nM	CIMETIDINE
5.19	IC50	6500	nM	NIFEKALANT
5.17	IC50	6700	nM	SUMATRIPTAN
5.14	IC50	7300	nM	RIMANTADINE
5.11	IC50	7800	nM	INDINAVIR
5.10	IC50	7900	nM	IRINOTECAN
5.09	IC50	8100	nM	DABIGATRAN
5.08	IC50	8300	nM	RANITIDINE

PubChem BioAssay actives

55 with measured affinity, of 149 total; 35 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
Ondansetron	721746: Inhibition of human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells after 5 mins by liquid scintillation counting analysis	ic50	0.0100	uM
Imatinib	721746: Inhibition of human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells after 5 mins by liquid scintillation counting analysis	ic50	0.0400	uM
Ritonavir	721747: Inhibition of human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells after 1.5 mins by scintillation counting analysis	ic50	0.0800	uM
Mitoxantrone	721746: Inhibition of human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells after 5 mins by liquid scintillation counting analysis	ic50	0.1900	uM
Pentamidine	721746: Inhibition of human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells after 5 mins by liquid scintillation counting analysis	ic50	0.4100	uM
ethyl 4-[6-(diaminomethylideneamino)hexanoyloxy]benzoate	721754: Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	ic50	0.5000	uM
6-[2-[2-hydroxyethyl-[3-(4-nitrophenyl)propyl]amino]ethylamino]-1,3-dimethylpyrimidine-2,4-dione	721746: Inhibition of human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells after 5 mins by liquid scintillation counting analysis	ic50	0.6500	uM
Chlorhexidine	721754: Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	ic50	0.7000	uM
Famotidine	721754: Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	ic50	0.7600	uM
1,2,3,4-tetrahydroacridin-9-amine	692195: Inhibition of human MATE1 expressed in HEK-293-Flp-In cells incubated for 3 mins by ASP+ substrate uptake assay	ic50	1.1000	uM
Epinastine	721754: Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	ic50	1.1000	uM
Cimetidine	721754: Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	ic50	1.2000	uM
Zafirlukast	721754: Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	ic50	1.3000	uM
Topotecan	721754: Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	ic50	1.3000	uM
Prazosin	721754: Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	ic50	1.6000	uM
Risperidone	721754: Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	ic50	1.6000	uM
Buspirone	721754: Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	ic50	1.7000	uM
(2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide;hydrate	721747: Inhibition of human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells after 1.5 mins by scintillation counting analysis	ic50	1.7000	uM
Vecuronium Bromide	721754: Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	ic50	1.9000	uM
N-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]pyrimidin-2-amine	1848080: Inhibition of human MATE1	ic50	2.0000	uM
Irinotecan	721747: Inhibition of human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells after 1.5 mins by scintillation counting analysis	ic50	2.1000	uM
Domperidone	721754: Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	ic50	2.3000	uM
4-methyl-6-[4-[[(3S,5R)-3-methyl-5-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)piperazin-1-yl]methyl]triazol-2-yl]pyridine-3-carbonitrile	2077521: Inhibition of MATE1 (unknown origin)	ic50	2.7000	uM
Dihydroergotamine	721754: Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	ic50	2.8000	uM
Pantoprazole	721746: Inhibition of human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells after 5 mins by liquid scintillation counting analysis	ic50	2.8000	uM
[4-[2-[2-(dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4-(diaminomethylideneamino)benzoate	721754: Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	ic50	2.9000	uM
1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)indazole-3-carboxamide	721754: Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	ic50	5.0000	uM
2,4-dichloro-6-(3,5-dichloro-2-hydroxyphenyl)sulfanylphenol	721754: Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	ic50	5.2000	uM
Sumatriptan	721754: Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	ic50	6.7000	uM
Rimantadine	721754: Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	ic50	7.3000	uM
Dabigatran	721754: Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	ic50	8.1000	uM
1-N’-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine	721754: Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	ic50	8.3000	uM
Tubocurarine	721754: Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	ic50	9.4000	uM
(1S,2S)-6-(5-ethylsulfonyl-1,3-benzoxazol-2-yl)-1,2-dihydronaphthalene-1,2-diol	1580335: Inhibition of MATE1 (unknown origin)	ic50	10.0000	uM
Imipramine	692195: Inhibition of human MATE1 expressed in HEK-293-Flp-In cells incubated for 3 mins by ASP+ substrate uptake assay	ic50	10.0000	uM

CTD chemical–gene interactions

113 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tetraethylammonium	increases import, affects uptake, decreases reaction, increases uptake, affects transport (+1 more)	7
Estradiol	affects cotreatment, decreases expression, increases expression	5
Metformin	decreases reaction, increases uptake, decreases uptake	5
Paraquat	decreases reaction, increases uptake, increases expression, affects uptake, decreases uptake (+1 more)	4
Valproic Acid	affects expression, affects cotreatment, increases expression	4
Verapamil	decreases reaction, increases import, increases uptake, decreases activity	4
Benzo(a)pyrene	affects methylation, decreases expression, increases methylation	3
Cimetidine	affects transport, decreases reaction, increases uptake, decreases activity	3
Aflatoxin B1	affects expression, decreases expression, increases methylation	3
bisphenol A	affects cotreatment, increases methylation, decreases reaction, increases uptake, decreases activity (+1 more)	2
tetrabutylammonium	decreases reaction, increases uptake, affects uptake	2
tetramethylammonium	affects reaction, increases uptake, affects uptake, decreases reaction	2
tetrapropylammonium	affects uptake, decreases reaction, increases uptake	2
entinostat	affects cotreatment, increases expression	2
Oxaliplatin	decreases uptake, increases uptake	2
Amiloride	decreases activity, decreases reaction, increases uptake	2
Imipramine	decreases reaction, increases uptake, decreases activity	2
Progesterone	affects cotreatment, decreases expression, increases expression	2
Pyrimethamine	decreases reaction, increases uptake, decreases activity	2
Quinidine	decreases activity, decreases reaction, increases uptake	2
Tacrine	increases uptake, decreases reaction	2
Tobacco Smoke Pollution	decreases reaction, increases import, decreases expression	2
1-Methyl-4-phenylpyridinium	decreases reaction, increases uptake, decreases activity, affects reaction	2
Cyclosporine	decreases expression	2
Ondansetron	decreases reaction, increases uptake	2
bisphenol F	decreases reaction, increases uptake	1
ethohexadiol	affects reaction, increases uptake	1
methyleugenol	decreases expression	1
nuciferine	decreases reaction, increases uptake	1
cinchonine	decreases reaction, increases uptake	1

ChEMBL screening assays

21 unique, capped per target: 16 binding, 4 admet, 1 toxicity

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1743155	ADMET	Substrates of transporters of clinical importance in the absorption and disposition of drugs, MATE1	Membrane transporters in drug development. — Nat Rev Drug Discov
CHEMBL2320298	Binding	Inhibition of human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells after 5 mins by liquid scintillation counting analysis	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. — J Med Chem
CHEMBL5099091	Toxicity	Inhibition of human MATE1	Fluorophenylalkyl-substituted cyanoguanidine derivatives as bacteria-selective MATE transporter inhibitors for the treatment of antibiotic-resistant infections. — Bioorg Med Chem

Cellosaurus cell lines

7 cell lines: 4 cancer cell line, 2 transformed cell line, 1 induced pluripotent stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B6AD	HepaRG MATE1 KO	Cancer cell line	Female
CVCL_B6AV	SA7K MATE1 KO	Transformed cell line	Female
CVCL_B6AW	SA7K MATE1/MATE2K KO	Transformed cell line	Female
CVCL_C3LG	STBCi322-A-6	Induced pluripotent stem cell	Female
CVCL_D4TV	HuH7-SLC47A1-KO-c4	Cancer cell line	Male
CVCL_D4TW	HuH7-SLC47A1-KO-c7	Cancer cell line	Male
CVCL_TN85	HAP1 SLC47A1 (-)	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.